Parinam advised Serum Institute of India group company, leading Indian manufacturer of vaccines for making an investment into a company manufacturing ICMR approved SARS-COV/ RT-PCR testing kits by subscribing to debentures and further issues of shares against licensing of intellectual property valued at INR 800 crores (approximately). Assisted in the negotiation, execution and closing of the securities subscription agreement, security holders’ agreement and other transaction documents
